Barclays PLC Purchases 118,438 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)

Barclays PLC grew its position in IDEAYA Biosciences, Inc. (NASDAQ:IDYA - Free Report) by 188.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 181,170 shares of the company's stock after buying an additional 118,438 shares during the period. Barclays PLC owned approximately 0.21% of IDEAYA Biosciences worth $5,739,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in IDYA. Allworth Financial LP grew its stake in shares of IDEAYA Biosciences by 800.0% during the 3rd quarter. Allworth Financial LP now owns 900 shares of the company's stock worth $29,000 after acquiring an additional 800 shares in the last quarter. Covestor Ltd grew its position in IDEAYA Biosciences by 23,050.0% in the third quarter. Covestor Ltd now owns 926 shares of the company's stock valued at $29,000 after purchasing an additional 922 shares in the last quarter. Quest Partners LLC acquired a new stake in IDEAYA Biosciences in the 2nd quarter valued at $41,000. US Bancorp DE boosted its stake in shares of IDEAYA Biosciences by 67.2% during the 3rd quarter. US Bancorp DE now owns 1,714 shares of the company's stock worth $54,000 after buying an additional 689 shares during the last quarter. Finally, Daiwa Securities Group Inc. grew its holdings in shares of IDEAYA Biosciences by 637.9% in the 2nd quarter. Daiwa Securities Group Inc. now owns 1,948 shares of the company's stock valued at $68,000 after acquiring an additional 1,684 shares in the last quarter. Institutional investors own 98.29% of the company's stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Stephens assumed coverage on IDEAYA Biosciences in a research report on Monday, November 18th. They set an "overweight" rating and a $51.00 price target for the company. Oppenheimer reiterated an "outperform" rating and issued a $53.00 price objective on shares of IDEAYA Biosciences in a report on Tuesday, October 29th. Citigroup reduced their target price on IDEAYA Biosciences from $60.00 to $58.00 and set a "buy" rating on the stock in a report on Tuesday, August 27th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $61.00 price objective on shares of IDEAYA Biosciences in a research report on Tuesday, September 24th. Finally, Cantor Fitzgerald reissued an "overweight" rating on shares of IDEAYA Biosciences in a report on Tuesday. Two equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $53.67.

IDEAYA Biosciences Trading Up 3.3 %

NASDAQ IDYA traded up $0.82 during mid-day trading on Friday, hitting $25.61. The company's stock had a trading volume of 1,937,098 shares, compared to its average volume of 870,979. The company's 50 day simple moving average is $28.28 and its 200 day simple moving average is $34.01. IDEAYA Biosciences, Inc. has a twelve month low of $24.48 and a twelve month high of $47.74. The firm has a market capitalization of $2.21 billion, a price-to-earnings ratio of -10.99 and a beta of 0.79.

IDEAYA Biosciences (NASDAQ:IDYA - Get Free Report) last posted its earnings results on Monday, November 4th. The company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($0.63) by $0.03. During the same quarter last year, the business posted ($0.46) earnings per share. As a group, research analysts forecast that IDEAYA Biosciences, Inc. will post -2.45 EPS for the current year.

IDEAYA Biosciences Company Profile

IDEAYA Biosciences, Inc, a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability.